What caused the pre-market move in MMTX.SW stock today?

The pre-market gain of **8.98%** is driven by elevated volume of **721,551** shares and short-covering after steep YTD declines. No confirmed corporate announcement was cited; traders reacted to technical oversold conditions and renewed interest in small-cap biotech names.

What is Meyka AI’s rating for MMTX.SW stock and what does it mean?

Meyka AI rates MMTX.SW **62.65/100 (Grade B, HOLD)**, reflecting sector and benchmark comparisons, growth metrics and forecasts. The grade is informational and not financial advice; investors should combine it with their own research.

What are realistic price targets for MMTX.SW stock?

Scenario targets: conservative **CHF 0.60**, base case **CHF 1.10** (50-day avg), long-term **CHF 1.26** (200-day avg). From **CHF 0.48**, these imply +25.00%, +129.17% and +162.50% respectively under recovery scenarios.

How risky is trading MMTX.SW stock right now?

Risk is high: deep oversold technicals (RSI **10.26**), negative OBV, no EPS disclosure, and post-IPO volatility. Use strict position sizing, monitor volume and catalyst announcements, and expect wide intraday swings on the SIX.

CH Stocks

MMTX.SW +8.98% pre-market on SIX: MindMaze Therapeutics CHF 0.48, catalysts

ByDanny Kontos March 16, 2026

MMTX.SW stock is trading higher in pre-market on 16 Mar 2026 after a one-day jump of 8.98%, lifting MindMaze Therapeutics Holding S.A. to CHF 0.48 on the SIX Swiss Exchange. Volume is elevated at 721,551 shares versus a 30-day average of 441,470, giving a relative volume of 1.63 and suggesting real intraday interest. The move follows renewed investor focus on the healthcare biotechnology group since its December 2025 IPO and wider sector weakness that is rewarding volatile small caps with short-term rebounds. We examine what is driving the gain, technical signals, and scenario-based price targets.